Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or
‘the Company’), a pharmaceutical company developing proprietary
drugs which use cannabis as an ingredient for unmet medical needs,
psychedelic-assisted psychotherapy protocols, and an operator of
psychedelic-assisted psychotherapy clinics, is pleased to announce
that three of the world’s top psychedelic therapy and science
experts have joined the Advisory Board of Clarion Clinics Group.
Clarion Clinics Group Pty Ltd is a collaborative
venture between IHL and three leading Australian psychedelics
experts, Dr. Paul Liknaitzky, Prof. Suresh Sundram and Sean
O’Carroll, who are co-founders, key executives and directors of the
company. Clarion’s first clinic will open its doors to patients in
Q3 2023 and the company intends to expand rapidly following the
successful operation of the first clinic.
The company is delighted to announce that, in
addition to the most experienced psychedelics professionals in
Australia taking key executive roles and directorships in the
Clarion Clinics Group, three of the world’s most experienced and
leading clinical psychedelic experts have joined its Advisory
Board.
Dr. Bill Richards
Bill is the Director of Therapy at Sunstone
Therapies, is a psychologist in the Center for Psychedelic and
Consciousness Research at the Johns Hopkins School of Medicine, a
consultant/trainer within numerous psychedelic research sites
internationally, a teacher in the Program of Psychedelic Therapy
and Research at the California Institute of Integral Studies, and
also a clinician in private practice in Baltimore. His involvement
with psilocybin research originated in 1963, and from 1967 to 1977
he pursued psychotherapy research with LSD, DPT, MDA and psilocybin
at the Maryland Psychiatric Research Center, including protocols
designed to investigate the promise of psychedelic substances in
the treatment of alcoholism, depression, addictions, and the
psychological distress associated with terminal cancer, alongside
their use in the training of religious and mental-health
professionals. In 1999 at Johns Hopkins, he and Roland Griffiths
launched the rebirth of psilocybin research after a 22-year period
of dormancy in the United States.
Dr. Andrea Jungaberle
Andrea serves as the Medical
Director of the OVID Clinics in Berlin, and is a co-founder
and advisory board member of the MIND Foundation. Andrea is a
clinical specialist in anaesthesia and emergency medicine, a
psychedelic therapist, and currently completing a
certification in cognitive behavioural psychotherapy. She is
a published author, workshop leader, yoga teacher,
and has participated in several accredited trainings in
psychedelic therapy. She is part of the EPIsoDE study team,
using psilocybin-assisted psychotherapy
to treat 144 depressive patients, and is a site
Principal Investigator in Beckley Psytech’s Phase IIa study on
5MeO-DMT in treatment resistant depression. In her role as Medical
Director of OVID Clinics, she has conducted and/or
supervised more than 1400 Ketamine applications within a
psychedelic-assisted psychotherapy paradigm in over 270
patients.
Prof. Matthew Johnson
Matthew is Professor of Psychiatry and
Behavioral Sciences at Johns Hopkins. He is one of the world’s most
published scientists on the human effects of psychedelics, and has
conducted seminal research in the behavioral economics of drug use,
addiction, and risk behaviour. Working with psychedelics since
2004, he published psychedelic safety guidelines in 2008, helping
to resurrect psychedelic research. As Principal Investigator, he
developed and published the first research on psychedelic treatment
of tobacco addiction in 2014. He is Principal Investigator on
funded studies investigating psilocybin in the treatment of opioid
dependence and PTSD. Beyond psilocybin, in 2011 Dr. Johnson
published the first-ever blinded human research showing
psychoactive effects of salvinorin A, and in
2017 published the first data indicating that MDMA pill
testing services may reduce harm. He has published studies on drugs
across nearly all psychoactive classes, including studies of
cocaine, methamphetamine, tobacco/nicotine, alcohol, opioids,
cannabis, benzodiazepines, psilocybin, dextromethorphan, salvinorin
A, GHB, caffeine, and cathinone analogs compounds. He has
received continuous NIH funding as Principal Investigator since
2009, has provided invited presentations in 13 nations, and has
been interviewed widely by media about psychedelics and other
drugs.
Dr Paul Liknaitzky: Co-Founder, Director, Chief
Strategy Officer, and Chief Scientific Officer, Clarion Clinics
Group, said “Bill, Andrea and Matt are wonderful colleagues and
inspiring people. Each bring deep experience and hard-won wisdom
that will help guide our efforts within the Clarion venture towards
supporting our clients to live their best lives. I’m grateful for
their trust and support.”
Peter Widdows, Incannex Director, said: “I’m
delighted and honoured that such esteemed professionals have
decided to join the Clarion Clinics team. It’s a testament to the
vision that Paul, Suresh and Sean are bringing together to provide
this vital service to many people in great need. As Australia is
the first country to legalise the use of psychedelic drugs in the
treatment of mental illness, the eyes of the world are upon us, and
having people of this calibre and experience on board will help us
ensure we provide world-leading effective treatments in an ethical
and safe way.”
Joel Latham, IHL Managing Director and CEO,
said: “When people with the global reputations of Bill, Matthew and
Andrea wish to help shape your venture, you know you’ve hit on
something special; something which could help improve the lives of
millions of people around the world.”
This announcement has been approved for
release to ASX by the Incannex Board of Directors.
About Incannex Healthcare
Limited
Incannex is a clinical stage pharmaceutical
development company that is developing unique medicinal cannabis
pharmaceutical products and psychedelic medicine therapies for the
treatment of obstructive sleep apnoea (OSA), traumatic brain injury
(TBI) and concussion, lung inflammation (ARDS, COPD, asthma,
bronchitis), rheumatoid arthritis, inflammatory bowel disease,
anxiety disorders, addiction disorders, and pain, among other
indications.
U.S. FDA approval and registration, subject to
ongoing clinical success, is being pursued for each drug and
therapy under development. Each indication under investigation
currently has no, or limited, existing registered pharmacotherapy
(drug) treatments available to the public and represent major
global economic opportunities to Incannex and its shareholders.
Incannex has a strong patent filing strategy in
place as it develops its products and therapies in conjunction with
its medical and scientific advisory board and partners. The Company
holds 19 granted patents and 30 pending patent applications.
Incannex is listed on the Australian Stock Exchange (ASX) with
stock code “IHL” and has American Depository Shares listed on
NASDAQ under code “IXHL”.
Website:
www.incannex.com.au Investors:
investors@incannex.com.au
Forward-looking statementsThis
press release contains "forward-looking statements" within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are made as of the date they were first issued and were
based on current expectations and estimates, as well as the beliefs
and assumptions of management. The forward-looking statements
included in this press release represent Incannex's views as of the
date of this press release. Incannex anticipates that subsequent
events and developments may cause its views to change. Incannex
undertakes no intention or obligation to update or revise any
forward-looking statements, whether as of a result of new
information, future events or otherwise. These forward-looking
statements should not be relied upon as representing Incannex's
views as of any date after the date of this press release.
Contact Information:
Incannex Healthcare LimitedMr
Joel LathamManaging Director and Chief Executive Officer+61 409 840
786joel@incannex.com.au
Investor Relations Contact – United States
Alyssa Factor Edison Group+1 (860) 573
9637afactor@edisongroup.com
Incannex Healthcare (NASDAQ:IXHL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Incannex Healthcare (NASDAQ:IXHL)
Historical Stock Chart
From Sep 2023 to Sep 2024